Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments
To compare the efficacy of adding liraglutide versus adding IAsp to the largest meal on top of IDeg OD + metformin in controlling glycaemia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk Pharmaceuticals Ltd
MAJ Il y a 4 ans
4T study Treating to Target in Type 2 Diabetes A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a Twice Daily Insulin Mixture versus a Meal-time Rapid-Acting Insulin in Subjects with Type 2 Diabetes Inadequately Controlled on Therapy with Oral Agents, and Assessing the Requirement for more Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, their Efficacy and Durability
Over 12 months: to compare the ability of three different single insulin formulation regimens to achieve good glycaemic control, defined as HbA1C levels ≤6.5 %, when added to current oral anti-diabet...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency
To characterise the pharmacokinetics of rFXIII in paediatric subjects (1 to less than 6 years old) with congenital FXIII A-subunit deficiency following a single intravenous dose administration by meas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit
The primary objective is to evaluate the effect of Norditropin® on final height in children with Noonan syndrome
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk Pharmaceutique S.A.S
MAJ Il y a 4 ans
To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy
The primary objective of this study is to investigate how easy/difficult patients/parents assess growth hormone injection using Norditropin NordiFlex® by quantifying the proportion of patients that fi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B
To evaluate immunogenicity of N9-GP (nonacog beta pegol)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms. Trial Phase: IIIa
To evaluate the endometrial hyperplasia rate from endometrial biopsies taken at the beginning and at the end of study treatment (12 months).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes Mellitus treated with insulin
To compare the effect of once-daily dosing of three dose levels of oral semaglutide (3, 7 and 14 mg) versus placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with insulin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes
To compare the effect of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral semaglutide versus sitagliptin 100 mg once-daily, both in combination with metformin with or without sulf...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
The primary objective of this trial is to evaluate the efficacy of rFVIIa (NovoSeven®/Niastase®) in reducing disability and improving clinical outcome by preventing early haematoma growth in patients ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant